abstract: BACKGROUND: Data describing the true extent of antiretroviral therapy (ART)-induced @entity10 and @entity11 resistance in perinatally infected @entity0 on ART in Africa are sparse. METHODS: Fasting total @entity1 , low-density lipoprotein (LDL), high-density lipoprotein (HDL), @entity8 , @entity11 and @entity4 were performed on the first 100 of 190 pediatric ART clinic attendees. Diet assessment was performed by a trained dietician. @entity12 was formally graded by consensus between 2 expert @entity6 pediatricians. Durations of previous ART exposures, clinical stage, pre-ART viral load, nadir and current @entity2 were recorded. Dual-energy X-ray absorptiometry was performed on a subset of 42 @entity0 selected semi-randomly. RESULTS: Prevalences of @entity11 resistance, abnormal total @entity1 , LDL, HDL and @entity3 were 10%, 13%, 12%, 13% and 9%, respectively. Overall, 40% had at least 1 lipid abnormality or @entity11 resistance. Adjusted mean LDL @entity1 increased by 0.24 mmol/L for each additional year of cumulative @entity13 /r exposure (P = 0.03) after correcting for age, gender, body mass index, previous @entity14 exposure, age at ART initiation, dietary fat and refined @entity9 , whereas adjusted mean LDL @entity1 was 0.9 mmol/L higher in @entity0 exposed to efavirenz within the previous 6 months (P = 0.02). Adjusting for age, gender and ethnicity, dual-energy X-ray absorptiometry revealed that greater trunk fat and lower peripheral subcutaneous fat were associated with elevated @entity8 but not with total @entity1 , LDL, HDL or homeostatic model assessment. Similarly, the presence of visually obvious @entity12 was associated with elevated @entity8 but not with total @entity1 , LDL, HDL, homeostatic model assessment or @entity7 . CONCLUSIONS: Prevalences of @entity11 resistance and @entity10 were high. Cumulative @entity13 is an independent risk factor for @entity10 , with @entity5 exposure having only transitory effect.

title: High Prevalence of @entity10 and @entity11 Resistance in XXXX -infected Prepubertal African Children on Antiretroviral Therapy.

answer: @entity6


abstract: BACKGROUND: Data describing the true extent of antiretroviral therapy (ART)-induced @entity10 and @entity11 resistance in perinatally infected @entity0 on ART in Africa are sparse. METHODS: Fasting total @entity1 , low-density lipoprotein (LDL), high-density lipoprotein (HDL), @entity8 , @entity11 and @entity4 were performed on the first 100 of 190 pediatric ART clinic attendees. Diet assessment was performed by a trained dietician. @entity12 was formally graded by consensus between 2 expert @entity6 pediatricians. Durations of previous ART exposures, clinical stage, pre-ART viral load, nadir and current @entity2 were recorded. Dual-energy X-ray absorptiometry was performed on a subset of 42 @entity0 selected semi-randomly. RESULTS: Prevalences of @entity11 resistance, abnormal total @entity1 , LDL, HDL and @entity3 were 10%, 13%, 12%, 13% and 9%, respectively. Overall, 40% had at least 1 lipid abnormality or @entity11 resistance. Adjusted mean LDL @entity1 increased by 0.24 mmol/L for each additional year of cumulative @entity13 /r exposure (P = 0.03) after correcting for age, gender, body mass index, previous @entity14 exposure, age at ART initiation, dietary fat and refined @entity9 , whereas adjusted mean LDL @entity1 was 0.9 mmol/L higher in @entity0 exposed to efavirenz within the previous 6 months (P = 0.02). Adjusting for age, gender and ethnicity, dual-energy X-ray absorptiometry revealed that greater trunk fat and lower peripheral subcutaneous fat were associated with elevated @entity8 but not with total @entity1 , LDL, HDL or homeostatic model assessment. Similarly, the presence of visually obvious @entity12 was associated with elevated @entity8 but not with total @entity1 , LDL, HDL, homeostatic model assessment or @entity7 . CONCLUSIONS: Prevalences of @entity11 resistance and @entity10 were high. Cumulative @entity13 is an independent risk factor for @entity10 , with @entity5 exposure having only transitory effect.

title: High Prevalence of XXXX and @entity11 Resistance in @entity6 -infected Prepubertal African Children on Antiretroviral Therapy.

answer: @entity10


abstract: BACKGROUND: Data describing the true extent of antiretroviral therapy (ART)-induced @entity10 and @entity11 resistance in perinatally infected @entity0 on ART in Africa are sparse. METHODS: Fasting total @entity1 , low-density lipoprotein (LDL), high-density lipoprotein (HDL), @entity8 , @entity11 and @entity4 were performed on the first 100 of 190 pediatric ART clinic attendees. Diet assessment was performed by a trained dietician. @entity12 was formally graded by consensus between 2 expert @entity6 pediatricians. Durations of previous ART exposures, clinical stage, pre-ART viral load, nadir and current @entity2 were recorded. Dual-energy X-ray absorptiometry was performed on a subset of 42 @entity0 selected semi-randomly. RESULTS: Prevalences of @entity11 resistance, abnormal total @entity1 , LDL, HDL and @entity3 were 10%, 13%, 12%, 13% and 9%, respectively. Overall, 40% had at least 1 lipid abnormality or @entity11 resistance. Adjusted mean LDL @entity1 increased by 0.24 mmol/L for each additional year of cumulative @entity13 /r exposure (P = 0.03) after correcting for age, gender, body mass index, previous @entity14 exposure, age at ART initiation, dietary fat and refined @entity9 , whereas adjusted mean LDL @entity1 was 0.9 mmol/L higher in @entity0 exposed to efavirenz within the previous 6 months (P = 0.02). Adjusting for age, gender and ethnicity, dual-energy X-ray absorptiometry revealed that greater trunk fat and lower peripheral subcutaneous fat were associated with elevated @entity8 but not with total @entity1 , LDL, HDL or homeostatic model assessment. Similarly, the presence of visually obvious @entity12 was associated with elevated @entity8 but not with total @entity1 , LDL, HDL, homeostatic model assessment or @entity7 . CONCLUSIONS: Prevalences of @entity11 resistance and @entity10 were high. Cumulative @entity13 is an independent risk factor for @entity10 , with @entity5 exposure having only transitory effect.

title: High Prevalence of @entity10 and XXXX Resistance in @entity6 -infected Prepubertal African Children on Antiretroviral Therapy.

answer: @entity11


abstract: PURPOSE: @entity6 ( @entity6 ) is a progressive @entity5 of the hand/foot that often leads to debilitating functional impairment. In Europe, orthovoltage @entity4 ( @entity4 ) has been demonstrated to prevent @entity1 progression for up to 80% of @entity0 with early-stage @entity6 . There are limited data reporting outcomes for populations outside of Europe or using electron @entity4 . METHODS AND MATERIALS: Between 2008 and 2013, 44 early-stage @entity6 cases received @entity4 . @entity4 fields involved clinically defined targets encompassing involved areas (skin changes, cords, nodules) with at least 1.5-cm margins. En face electrons (6-12 MeV) and bolus (0.5-1 cm) were selected individually. Outcomes are reported for @entity0 who participated in an institutional review board-approved standardized questionnaire and chart review. RESULTS: Thirty-three @entity0 received 66 treatments (45 hands/15 feet and 6 reirradiations). Most frequent dose schemes were 21 Gy (3 Gy in 7 fractions) and 30 Gy (3 Gy in 10 fractions with 6- to 8-week breaks after 15 Gy). Median time to follow-up survey was 31 months. Disease progression at any location within or outside the @entity4 treatment field occurred in 20 of 33 @entity0 (61%). Fourteen of 60 sites (23%) developed in-field progression, but 4 sites were successfully reirradiated with final local control in 50 of 60 sites (83%). @entity4 improved pretreatment symptoms of @entity3 with strain at 30 of 37 sites (81%) and itch/burn sensations at 17 of 21 sites (81%). There were no reported grade >= 2 late @entity2 even with reirradiation. @entity0 reported overall success with treatment was 31 of 33 @entity0 (94%). CONCLUSION: @entity6 is a progressive disease. En face electron @entity4 is an effective therapy that stabilizes or improves symptoms in the majority of @entity0 . Reirradiation can be considered as a treatment option for in-field progression. @entity0 report minimal @entity2 and a high rate of satisfaction with treatment.

title: @entity0 -reported outcomes after electron radiation treatment for early-stage palmar and XXXX .

answer: @entity6


abstract: PURPOSE: @entity6 ( @entity6 ) is a progressive @entity5 of the hand/foot that often leads to debilitating functional impairment. In Europe, orthovoltage @entity4 ( @entity4 ) has been demonstrated to prevent @entity1 progression for up to 80% of @entity0 with early-stage @entity6 . There are limited data reporting outcomes for populations outside of Europe or using electron @entity4 . METHODS AND MATERIALS: Between 2008 and 2013, 44 early-stage @entity6 cases received @entity4 . @entity4 fields involved clinically defined targets encompassing involved areas (skin changes, cords, nodules) with at least 1.5-cm margins. En face electrons (6-12 MeV) and bolus (0.5-1 cm) were selected individually. Outcomes are reported for @entity0 who participated in an institutional review board-approved standardized questionnaire and chart review. RESULTS: Thirty-three @entity0 received 66 treatments (45 hands/15 feet and 6 reirradiations). Most frequent dose schemes were 21 Gy (3 Gy in 7 fractions) and 30 Gy (3 Gy in 10 fractions with 6- to 8-week breaks after 15 Gy). Median time to follow-up survey was 31 months. Disease progression at any location within or outside the @entity4 treatment field occurred in 20 of 33 @entity0 (61%). Fourteen of 60 sites (23%) developed in-field progression, but 4 sites were successfully reirradiated with final local control in 50 of 60 sites (83%). @entity4 improved pretreatment symptoms of @entity3 with strain at 30 of 37 sites (81%) and itch/burn sensations at 17 of 21 sites (81%). There were no reported grade >= 2 late @entity2 even with reirradiation. @entity0 reported overall success with treatment was 31 of 33 @entity0 (94%). CONCLUSION: @entity6 is a progressive disease. En face electron @entity4 is an effective therapy that stabilizes or improves symptoms in the majority of @entity0 . Reirradiation can be considered as a treatment option for in-field progression. @entity0 report minimal @entity2 and a high rate of satisfaction with treatment.

title: XXXX -reported outcomes after electron radiation treatment for early-stage palmar and @entity6 .

answer: @entity0


abstract: UNASSIGNED: MicroRNA-153 (miR-153) is considered to be a @entity1 regulator. Silencing of miR-153 expression induced apoptosis in @entity0 cells. Data on mechanism suggest that up-regulation of miR-153 level promotes cell proliferation via the down regulation the expression of @entity4 or @entity8 , which attenuates the proliferation of cancerous cells. This study aims to identify the effect of miR-153 on the activity of chemotherapeutic Agents and targeted agents in @entity3 cells and to investigate the mechanisms involved. @entity2 , soft agar, trans-well and flow cytometry assays were performed to examine whether miR-153 down-regulated the activity of the chemotherapeutic and targeted drugs, @entity6 , @entity7 and @entity5 in HepG2 cells. The rate of proliferation inhibition, relative survival rates and IC50 values of each drug were calculated. Western blot and luciferase assays were performed to assess whether miR-153 modulates the expression of important genes related to cell proliferation, apoptosis and survival. Results showed that miR-153 attenuated the effect of @entity7 , @entity5 and @entity6 on HepG2 cells, the IC50 value increased from 0.25  0.01 mol/L to 1.02  0.14 mol/L, 0.05  0.01 mol/L to 0.14  0.02 mol/L and from 1.09  0.15 mol/L to 5.18  0.99 mol/L, respectively. In addition, miR-153 also reduced the effect of these drugs on SMMC-7721, BEL-7402 or Hu7 cell; and it also reduced the effects of @entity6 , @entity7 and @entity5 on anchor-independent growth of HepG2 cells. Over-expression of miR-153 down-regulated the activity of @entity7 and @entity5 on cell cycle arrest of HepG2 cells and the effect of @entity6 on the invasion and migration of HepG2 cells. Furthermore, overexpression of miR-153 also enhanced growth of HepG2, MHCC-97H, MHCC-97 L and L-02 cells. These results show that overexpression of miR-153 protects HepG2 cells against the effects of these chemotherapeutic drugs via multiple mechanisms, and miR-153 may be a novel target for @entity3 in future diagnostic and therapeutic interventions.

title: MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in XXXX Cells.

answer: @entity3


abstract: BACKGROUND: @entity3 (Tg), the major thyroidal protein, plays important roles in thyroid hormone biosynthesis and in @entity2 ( @entity2 ). Tg also serves as a pre- and postoperative biomarker of @entity0 ( @entity0 ). The endogenous b-galactoside binding lectin @entity4 ( @entity4 ), secreted by transformed thyroid cells, has been shown to be another useful biomarker of @entity0 . Tg contains @entity1 that can serve as binding epitopes of @entity4 . The objective of the study is to investigate the interaction between Tg and @entity4 and discuss its potential consequences. METHODS: Binding interaction between Tg and @entity4 was first studied by hemagglutination inhibition assays. Subsequently, a detailed analysis of binding thermodynamics was carried out by isothermal titration calorimetry. Quantitative precipitation was performed to study the complex formation between Tg and @entity4 and to determine the binding stoichiometry. The concentration-dependent rate and amount of complex formation between Tg and @entity4 was examined spectrophotometrically. A similar approach was taken to study the effect of free Tg and @entity4 on preformed Tg- @entity4 complex. RESULTS: Quantitative biochemical and biophysical data show that these two biomarkers produced by @entity0 cells interact with each other with submicromolar affinity and form an insoluble complex at their stoichiometric concentration. One Tg molecule could bind up to 14 molecules of @entity4 . Such complex formation mutually sequestered both Tg and @entity4 , decreasing the concentration of their freely available forms. Formation of the Tg- @entity4 complex was reversible as the preformed complex was dissolved by free Tg as well as free @entity4 . While free Tg rapidly dissolved preformed Tg- @entity4 complex in a concentration-dependent manner, @entity4 was found to be much less efficient and slowly dissolved only a fraction of the preformed complex at a relatively higher @entity4 concentration. CONCLUSIONS: Complex formation between Tg and @entity4 through high affinity binding and the sensitivity of the complex to free Tg and @entity4 can potentially influence their biological functions. Interactions between Tg and @entity4 might also interfere with their clinical detection, the same way Tg autoantibody (TgAb) is reported to interfere with Tg assays. The data support a model of @entity4 -mediated homeostatic process of Tg.

title: Glycan-Dependent Mutual and Reversible Sequestration of Two XXXX .

answer: @entity0


abstract: STUDY DESIGN: Validation study. OBJECTIVE: To investigate the most valid, reliable, and comprehensible response scale for spinal @entity1 @entity0 to compare their current level of function and health with their preinjury state. SUMMARY OF BACKGROUND DATA: In the context of a main project of the AOSpine Knowledge Forum @entity1 to develop a disease-specific outcome instrument for adult spinal @entity1 @entity0 , the need to identify a response scale that uniquely reflects the degree to which a spine @entity1 @entity0 has returned to his or her preinjury state is crucial. METHODS: In the first phase, 3 different question formats and 3 different response formats were investigated in a questionnaire, which was administered twice. Based on the results of the first phase, in the second phase, a modified questionnaire was administered once to a second group of @entity0 to investigate 5 different response formats: 0-10 Numeric Rating Scale-11, 0-100 Numeric Rating Scale-101, Visual Analogue Scale, Verbal Rating Scale, and Adjective Scale. All @entity0 were interviewed in a semistructured fashion to identify their preferences. Multiple statistical analyses were performed: test-retest reliability, internal consistency, and discriminant validity. RESULTS: Twenty eligible @entity0 were enrolled in the first phase and 59 in the second phase. The initial phase revealed the highest preference for 1 specific question format (60.0% and 86.7% after the first and second administration of the questionnaire, respectively). The second phase showed the Verbal Rating Scale as the most preferred response format (35.6%). The semistructured interviews revealed that overall, a subgroup of @entity0 preferred a verbal response format (42.4%), and another group of @entity0 preferred a numerical response format (49.1%). The statistical analysis showed good to excellent psychometric properties for all formats. CONCLUSION: The most preferred question and response formats were identified for use in a disease-specific outcome instrument for spinal @entity1 @entity0 . LEVEL OF EVIDENCE: 3.

title: Toward a Specific Outcome Instrument for Spinal XXXX : How to Measure Function and Health.

answer: @entity1


abstract: OBJECTIVE: Investigate the incidence of @entity1 during 1953-2013 and estimate the prevalence rate of @entity1 on 1 January 2003 and 2013 in Hordaland County, Western Norway. METHODS: All @entity0 with onset of disease in Hordaland 1953-2013 were identified in files from previous studies until 2003 and from @entity0 records at the departments of Neurology, Haukeland University Hospital and Haugesund Hospital during 2003-2013. 1558 @entity0 were assessed and 1402 of these were included, of whom 1035 were alive and living in Hordaland at prevalence day 1 January 2013. Annual incidence rates were calculated for 1953-2013. RESULTS: On 1 January 2003, the crude prevalence rate was 191/100   000 population and on 1 January 2013, the crude prevalence rate was 211.4 (95% CI 198.3 to 224.2) per 100   000; 270.9 (95% CI 250.6 to 292.3) for @entity0 and 151.8 (95% CI 136.8 to 167.9) for @entity0 . Prevalence peaked at ages 55-59   years for @entity0 and 60-64   years for @entity0 . The annual incidence rate increased from 1.9 (95% CI 1.2 to 2.6) per 100   000 during 1953-1957 to 7.2 (95% CI 6.0 to 8.5) during 1978-1982 and to 8.5 (95% CI 7.3 to 9.7) during 2003-2007, thus indicating a stabilising incidence over the past 35   years. The female/male ratio ranged from 1.2:1 to 1.8:1 (p=0.381) during the period. CONCLUSIONS: Stabilising rather than increasing incidence combined with the stable female/male ratio are indicative of non-fluctuating environmental factors in a geographical area otherwise characterised by lack of @entity2 effective sun exposure. The rising prevalence of @entity1 could result from improved survival and follow-up methodology.

title: A 60-year follow-up of the incidence and prevalence of XXXX in Hordaland County, Western Norway.

answer: @entity1


abstract: AIM: Primary @entity3 (PTL) is an uncommon and aggressive form of extranodal @entity6 ( @entity6 ). We aimed to analyse the clinicopathological characteristics and outcomes of our PTL cases. MATERIALS AND METHODS: A review was made of the medical records of 339 @entity6 @entity0 who were treated in the Medical Oncology Department between January 2005 and December 2013. RESULTS: 8 PTL @entity0 were identified from the 339 @entity6 @entity0 . The average age of the @entity0 was 67.7    7.9 years (range 53-79 years). The mean follow-up time was 24.8 months (range 7-98 months). Inguinal orchiectomy was performed as a diagnostic and initial therapy and all the @entity0 underwent 4-6 cycles of chemoimmunotherapy consisting of @entity4 , @entity2 , @entity5 and @entity1 plus rituximab. 4 of 8 @entity0 received intrathecal prophylactic chemotherapy and 6 of 8 @entity0 continued contralateral testis irradiation. Relapse occured in only 1 @entity0 in central nervous system after 6 months who had not received intrathecal prophylaxis. No contralateral testis relapse was observed. CONCLUSIONS: Primary @entity6 is an uncommon entity and we evaluated 8 @entity0 ; with one relapse in central nervous system and no relapse in the contralateral testis.

title: Primary XXXX : a single centre experience.

answer: @entity3


abstract: Cholinergic precursors increasing choline availability and acetylcholine synthesis/release may represent a therapeutic approach for countering @entity1 occurring in adult-onset @entity3 . Choline alphoscerate (alpha-gliceryl-phosphoryl-choline, @entity7 ) is among cholinergic precursors the most effective in enhancing acetylcholine biosynthesis and release in animal models. This study was designed to assess if a long-term treatment with @entity7 modify cerebrovascular components [perivascular astrocytes, blood-brain barrier (BBB) and microvessels] and endothelial inflammatory markers expression in spontaneously @entity2 @entity0 (SHR) used as a model of @entity5 . Male SHR aged 32 weeks and age-matched normotensive @entity0 -Kyoto @entity0 were treated for 4 weeks with @entity7 (150 mg/kg/day) or a vehicle. Intracerebral arteries of different brain areas, perivascular astrocytes, BBB and endothelial inflammatory markers were assessed by quantitative morphological and immunohistochemical techniques. No significant changes in the size of perivascular astrocytes were observed in SHR versus normotensive @entity0 -Kyoto @entity0 , whereas the expression of the BBB marker @entity6 increased in SHR. This phenomenon was countered by @entity7 treatment. On the contrary, @entity7 has no vasodilator effect on brain micro-vessels. Endothelial markers and vascular adhesion molecules expression were not homogeneously affected by @entity2 and @entity7 treatment in intracerebral vessels. The observation that treatment with @entity7 reversed BBB changes and countered to some extent micro-vessels changes occurring in SHR could explain data of clinical trials reporting an improvement of cognitive function in subjects suffering from @entity4 and treated with @entity7 . These preclinical data suggest that the compound could have a cerebrovascular protective effect deserving a further characterization.

title: Cerebrovascular and blood-brain barrier morphology in spontaneously XXXX @entity0 : effect of treatment with choline alphoscerate.

answer: @entity2


abstract: Cholinergic precursors increasing choline availability and acetylcholine synthesis/release may represent a therapeutic approach for countering @entity1 occurring in adult-onset @entity3 . Choline alphoscerate (alpha-gliceryl-phosphoryl-choline, @entity7 ) is among cholinergic precursors the most effective in enhancing acetylcholine biosynthesis and release in animal models. This study was designed to assess if a long-term treatment with @entity7 modify cerebrovascular components [perivascular astrocytes, blood-brain barrier (BBB) and microvessels] and endothelial inflammatory markers expression in spontaneously @entity2 @entity0 (SHR) used as a model of @entity5 . Male SHR aged 32 weeks and age-matched normotensive @entity0 -Kyoto @entity0 were treated for 4 weeks with @entity7 (150 mg/kg/day) or a vehicle. Intracerebral arteries of different brain areas, perivascular astrocytes, BBB and endothelial inflammatory markers were assessed by quantitative morphological and immunohistochemical techniques. No significant changes in the size of perivascular astrocytes were observed in SHR versus normotensive @entity0 -Kyoto @entity0 , whereas the expression of the BBB marker @entity6 increased in SHR. This phenomenon was countered by @entity7 treatment. On the contrary, @entity7 has no vasodilator effect on brain micro-vessels. Endothelial markers and vascular adhesion molecules expression were not homogeneously affected by @entity2 and @entity7 treatment in intracerebral vessels. The observation that treatment with @entity7 reversed BBB changes and countered to some extent micro-vessels changes occurring in SHR could explain data of clinical trials reporting an improvement of cognitive function in subjects suffering from @entity4 and treated with @entity7 . These preclinical data suggest that the compound could have a cerebrovascular protective effect deserving a further characterization.

title: Cerebrovascular and blood-brain barrier morphology in spontaneously @entity2 XXXX : effect of treatment with choline alphoscerate.

answer: @entity0


abstract: Our previous studies have demonstrated that addition of moderate volumes of absolute @entity2 (34-170 mM final concentration) to whole blood produces concentration-dependent @entity5 , due to release of @entity3 ( @entity3 ) from erythrocytes. We have now investigated the effects of exposure of blood to @entity4 by a more "physiologic" protocol, in which 7.8% (w/v) @entity2 is added to achieve a final concentration of 1 to 85 mM in @entity0 and @entity1 blood or platelet rich plasma ( @entity8 ). The effects of short incubation with @entity2 on @entity5 induced by @entity3 , collagen and @entity6 were examined by the impedance method of aggregometry. Aggregation induced by collagen in @entity8 of either species was significantly inhibited by 85 mM @entity4 , with concentrations as low as 4.25 mM inhibiting the response to collagen in @entity1 whole blood. @entity3 stimulated only primary, reversible aggregation in @entity1 @entity8 and whole blood, and these responses were unaffected by @entity2 . @entity0 platelets responded to @entity3 with irreversible aggregation, which was significantly attenuated by 85 mM @entity4 in whole blood but not @entity8 . @entity6 evoked irreversible @entity5 in all four preparations; this was significantly inhibited by the high dose @entity4 in @entity0 and @entity1 @entity8 , but not whole blood. In contrast to our earlier studies with absolute @entity4 , there was no evidence of @entity7 (and therefore, @entity3 release from red blood cells) using the current protocol. The results of these experiments show that @entity2 , at physiologically relevant concentrations, has an inhibitory effect on secondary @entity5 responses to some agonists in whole blood as well as @entity8 , possibly by its previously demonstrated effects on @entity6 release by phospholipases. The possibility remains to be considered that other blood cells might contribute to the effects of @entity2 on @entity5 in whole blood.

title: Inhibition of @entity5 in whole blood by XXXX .

answer: @entity2


abstract: Our previous studies have demonstrated that addition of moderate volumes of absolute @entity2 (34-170 mM final concentration) to whole blood produces concentration-dependent @entity5 , due to release of @entity3 ( @entity3 ) from erythrocytes. We have now investigated the effects of exposure of blood to @entity4 by a more "physiologic" protocol, in which 7.8% (w/v) @entity2 is added to achieve a final concentration of 1 to 85 mM in @entity0 and @entity1 blood or platelet rich plasma ( @entity8 ). The effects of short incubation with @entity2 on @entity5 induced by @entity3 , collagen and @entity6 were examined by the impedance method of aggregometry. Aggregation induced by collagen in @entity8 of either species was significantly inhibited by 85 mM @entity4 , with concentrations as low as 4.25 mM inhibiting the response to collagen in @entity1 whole blood. @entity3 stimulated only primary, reversible aggregation in @entity1 @entity8 and whole blood, and these responses were unaffected by @entity2 . @entity0 platelets responded to @entity3 with irreversible aggregation, which was significantly attenuated by 85 mM @entity4 in whole blood but not @entity8 . @entity6 evoked irreversible @entity5 in all four preparations; this was significantly inhibited by the high dose @entity4 in @entity0 and @entity1 @entity8 , but not whole blood. In contrast to our earlier studies with absolute @entity4 , there was no evidence of @entity7 (and therefore, @entity3 release from red blood cells) using the current protocol. The results of these experiments show that @entity2 , at physiologically relevant concentrations, has an inhibitory effect on secondary @entity5 responses to some agonists in whole blood as well as @entity8 , possibly by its previously demonstrated effects on @entity6 release by phospholipases. The possibility remains to be considered that other blood cells might contribute to the effects of @entity2 on @entity5 in whole blood.

title: Inhibition of XXXX in whole blood by @entity2 .

answer: @entity5


abstract: SUMMARYThe role of trace elements in @entity2 virulence is not yet known. The present study assessed the serum levels of two micronutrients, @entity3 and @entity1 , in cases of @entity2 . The study involved 96 @entity0 of whom 48 had either severe or non-severe forms of @entity2 (with and without warning signs), and the remaining 48 were @entity0 with other febrile illnesses (OFI), used as controls. Serum levels of @entity3 and @entity1 were evaluated at admission and by the time of defervescence using commercially available kits. At admission, no difference in the level of serum @entity3 was observed between cases and controls. In the group of @entity2 cases, the @entity3 level was found to be significantly decreased in severe and non-severe cases with warning signs, compared to non-severe cases without warning signs. In contrast, by the time of defervescence the @entity3 level was found to be increased in all @entity2 cases compared to OFI controls, but no difference was observed among @entity2 cases. Unlike OFI controls, @entity2 cases showed an increasing pattern of @entity3 levels from admission until defervescence. On the other hand, no such significant differences were observed in the serum level of @entity1 in the clinical groups, except for a decreased @entity1 level found in severe cases, compared to non-severe @entity2 without warning signs. The results show that @entity3 is associated with @entity2 severity and this finding emphasizes the need to investigate the involvement of trace elements in disease severity so as to improve the prognosis of @entity2 .

title: SERUM LEVELS OF @entity3 AND XXXX IN DENGUE FEVER.

answer: @entity1


abstract: SUMMARYThe role of trace elements in @entity2 virulence is not yet known. The present study assessed the serum levels of two micronutrients, @entity3 and @entity1 , in cases of @entity2 . The study involved 96 @entity0 of whom 48 had either severe or non-severe forms of @entity2 (with and without warning signs), and the remaining 48 were @entity0 with other febrile illnesses (OFI), used as controls. Serum levels of @entity3 and @entity1 were evaluated at admission and by the time of defervescence using commercially available kits. At admission, no difference in the level of serum @entity3 was observed between cases and controls. In the group of @entity2 cases, the @entity3 level was found to be significantly decreased in severe and non-severe cases with warning signs, compared to non-severe cases without warning signs. In contrast, by the time of defervescence the @entity3 level was found to be increased in all @entity2 cases compared to OFI controls, but no difference was observed among @entity2 cases. Unlike OFI controls, @entity2 cases showed an increasing pattern of @entity3 levels from admission until defervescence. On the other hand, no such significant differences were observed in the serum level of @entity1 in the clinical groups, except for a decreased @entity1 level found in severe cases, compared to non-severe @entity2 without warning signs. The results show that @entity3 is associated with @entity2 severity and this finding emphasizes the need to investigate the involvement of trace elements in disease severity so as to improve the prognosis of @entity2 .

title: SERUM LEVELS OF XXXX AND @entity1 IN DENGUE FEVER.

answer: @entity3


abstract: DNA vaccination of transchromosomal @entity1 (TcBs) with DNA vaccines expressing the codon-optimized (co) glycoprotein (GP) genes of Ebola virus (EBOV) and Sudan virus ( @entity4 ) produce fully human polyclonal antibodies (pAbs) that recognize both viruses and demonstrate robust neutralizing activity. Each TcB was vaccinated by intramuscular electroporation (IM-EP) a total of four times and at each administration received 10 mg of the EBOV-GPco DNA vaccine and 10 mg of the @entity4 -GPco DNA vaccine at two sites on the left and right sides, respectively. After two vaccinations, robust antibody responses (titers > 1000) were detected by ELISA against whole irradiated EBOV or @entity4 and recombinant EBOV-GP or @entity4 -GP (rGP) antigens, with higher titers observed for the rGP antigens. Strong, virus neutralizing antibody responses (titers >1000) were detected after three vaccinations when measured by @entity2 virus-based pseudovirion neutralization assay (PsVNA). Maximal neutralizing antibody responses were identified by traditional plaque reduction neutralization tests (PRNT) after four vaccinations. Neutralizing activity of human immunoglobulins (IgG) purified from TcB plasma collected after three vaccinations and injected intraperitoneally (IP) into @entity0 at a 100 mg/kg dose was detected in the serum by PsVNA up to 14 days after administration. Passive transfer by IP injection of the purified IgG (100 mg/kg) to groups of BALB/c @entity0 one day after IP challenge with @entity0 adapted (ma) EBOV resulted in 80% protection while all @entity0 treated with non-specific pAbs succumbed. Similarly, interferon receptor 1 knockout ( @entity3 -/-) @entity0 receiving the purified IgG (100 mg/kg) by IP injection one day after IP challenge with wild type @entity4 resulted in 89% survival. These results are the first to demonstrate that filovirus GP DNA vaccines administered to TcBs by IM-EP can elicit neutralizing antibodies that provide post-exposure protection. Additionally, these data describe production of fully human IgG in a large animal system, a system which is capable of producing large quantities of a clinical grade therapeutic product.

title: Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal XXXX Provide @entity0 with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

answer: @entity1


abstract: DNA vaccination of transchromosomal @entity1 (TcBs) with DNA vaccines expressing the codon-optimized (co) glycoprotein (GP) genes of Ebola virus (EBOV) and Sudan virus ( @entity4 ) produce fully human polyclonal antibodies (pAbs) that recognize both viruses and demonstrate robust neutralizing activity. Each TcB was vaccinated by intramuscular electroporation (IM-EP) a total of four times and at each administration received 10 mg of the EBOV-GPco DNA vaccine and 10 mg of the @entity4 -GPco DNA vaccine at two sites on the left and right sides, respectively. After two vaccinations, robust antibody responses (titers > 1000) were detected by ELISA against whole irradiated EBOV or @entity4 and recombinant EBOV-GP or @entity4 -GP (rGP) antigens, with higher titers observed for the rGP antigens. Strong, virus neutralizing antibody responses (titers >1000) were detected after three vaccinations when measured by @entity2 virus-based pseudovirion neutralization assay (PsVNA). Maximal neutralizing antibody responses were identified by traditional plaque reduction neutralization tests (PRNT) after four vaccinations. Neutralizing activity of human immunoglobulins (IgG) purified from TcB plasma collected after three vaccinations and injected intraperitoneally (IP) into @entity0 at a 100 mg/kg dose was detected in the serum by PsVNA up to 14 days after administration. Passive transfer by IP injection of the purified IgG (100 mg/kg) to groups of BALB/c @entity0 one day after IP challenge with @entity0 adapted (ma) EBOV resulted in 80% protection while all @entity0 treated with non-specific pAbs succumbed. Similarly, interferon receptor 1 knockout ( @entity3 -/-) @entity0 receiving the purified IgG (100 mg/kg) by IP injection one day after IP challenge with wild type @entity4 resulted in 89% survival. These results are the first to demonstrate that filovirus GP DNA vaccines administered to TcBs by IM-EP can elicit neutralizing antibodies that provide post-exposure protection. Additionally, these data describe production of fully human IgG in a large animal system, a system which is capable of producing large quantities of a clinical grade therapeutic product.

title: Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal @entity1 Provide XXXX with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

answer: @entity0


abstract: BACKGROUND AND PURPOSE: Investigations regarding @entity4 of carotid arteries showed an association between increased intima-media thickness and vascular risk factors. A newly developed three-dimensional ultrasound method increases the reproducibility of plaque volume measurements because more exact volume measurements can be performed with a reduction of the disadvantages of two-dimensional measurements. In a pilot study the influence of vascular risk factors on carotid artery plaque progression was examined. METHODS: Volumes of @entity3 plaques in carotid arteries in 54 @entity0 were measured with a three-dimensional ultrasound system during a 12-month period to determine the relationship between progression or regression of plaque volume, vascular risk factors, dose of @entity2 , and flow turbulence in the plaque region. RESULTS: A progression of plaque volume occurred in 67% (36/54) of all plaques. In no plaque was a regression of plaque volume seen. The optimal adjustment of all risk factors showed a significant influence on plaque progression (r = .31). Diastolic blood pressure was the strongest predictor of plaque progression (P < .01), followed by @entity1 (P < .03). Turbulence in the plaque region was found in 78% of the @entity0 in the progression group (n = 36) versus 61% in the nonprogression group (n = 18) but was not significant. Dose of @entity2 (100 mg versus 250/300 mg) had no influence on plaque volume after 1 year. CONCLUSIONS: Treatment of vascular risk factors reduces the progression of carotid artery plaque volume in three-dimensional ultrasound. The most important factor for plaque progression is a high diastolic blood pressure. Turbulence in the flow pattern and the examined doses of @entity2 showed no significant influence.

title: Influence of vascular risk factors for XXXX carotid artery plaque progression.

answer: @entity3


abstract: Various environmental signals integrate into a network of floral regulatory genes leading to the final decision on when to flower. Although a wealth of qualitative knowledge is available on how flowering time genes regulate each other, only a few studies incorporated this knowledge into predictive models. Such models are invaluable as they enable to investigate how various types of inputs are combined to give a quantitative readout. To investigate the effect of gene expression disturbances on flowering time, we developed a dynamic model for the regulation of flowering time in @entity0 . Model parameters were estimated based on expression time-courses for relevant genes, and a consistent set of flowering times for plants of various genetic backgrounds. Validation was performed by predicting changes in expression level in mutant backgrounds and comparing these predictions with independent expression data, and by comparison of predicted and experimental flowering times for several double mutants. Remarkably, the model predicts that a disturbance in a particular gene has not necessarily the largest impact on directly connected genes. For example, the model predicts that SUPPRESSOR OF OVEREXPRESSION OF CONSTANS ( @entity2 ) mutation has a larger impact on @entity3 ( @entity3 ), which is not directly regulated by @entity2 , compared to its effect on @entity1 (LFY) which is under direct control of @entity2 . This was confirmed by expression data. Another model prediction involves the importance of cooperativity in the regulation of @entity3 ( @entity3 ) by LFY, a prediction supported by experimental evidence. Concluding, our model for flowering time gene regulation enables to address how different quantitative inputs are combined into one quantitative output, flowering time.

title: A quantitative and dynamic model of the XXXX flowering time gene regulatory network.

answer: @entity0


abstract: UNASSIGNED: @entity4 (OM) can be metabolized to @entity3 in gastrointestinal ileocecal valve after oral administration, which affects pharmacological activity and reduce bioavailability of OM. A type of multiple-unit alginate-chitosan (Alg-Cs) floating beads was prepared by the ionotropic gelation method for gastroretention delivery of OM. A solid dispersion technique was applied and incorporated into beads to enhance the OM encapsulation efficiency (EE) and sustain the drug release. The surface morphology and internal hollow structure of beads were evaluated using optical microscopy and @entity2 ( @entity2 ). The developed Alg-Cs beads were spherical in shape with hollow internal structure and had particle size of 3.49        0.09   mm and 1.33        0.09   mm for wet and dried beads. Over 84% of the optimized OM solid dispersion-loaded Alg-Cs beads were able to continuously float over the simulated gastric fluid for 12   h in vitro. The OM solid dispersion-loaded Alg-Cs beads showed drug EE of 67.07%, which was much higher than that of beads loading with pure OM. Compared with the immediate release of OM capsules and pure OM-loaded beads, the release of OM from solid dispersion-loaded Alg-Cs beads was in a sustained-release manner for 12   h. Prolonged @entity1 time of over 8.5   h was achieved for OM solid dispersion-loaded Alg-Cs floating beads in healthy @entity0 in in vivo floating ability evaluated by X-ray imaging. The developed Alg-Cs beads loading with OM solid dispersion displayed excellent performance features characterized by excellent gastric floating ability, high drug EE and sustained-release pattern. The study illustrated the potential use of Alg-Cs floating beads combined with the solid dispersion technique for prolonging @entity1 and sustaining release of OM, which could provide a promising drug delivery system for gastric-specific delivery of OM for bioavailability enhancement.

title: Development and evaluation of alginate-chitosan gastric floating beads loading with XXXX solid dispersion.

answer: @entity4


abstract: UNASSIGNED: The diagnostic criteria for @entity2 ( @entity2 ) are continuously evolving. Here we investigated the clinical and molecular significance of different @entity1 ( @entity1 ) scores in transplant kidney biopsies. A total of 356 @entity0 with clinically indicated kidney transplant biopsies were classified into three groups based on @entity1 scores of 0, 1, 2, or more for Groups 1-3, respectively. Gene expression profiles were assessed using arrays on a representative subset of 93 @entity0 . The incidence of donor-specific anti-HLA antibodies was increased from 25% in Group 1 to 36% in Group 2 and to 54% in Group 3. Acute and chronic @entity2 were significantly more frequent in Group 3 (15% and 35%) compared with the Group 2 (3% and 15%) and Group 1 (0% and 5%), respectively. Gene expression profiles showed increased interferon-y and rejection-induced, cytotoxic and regulatory T-cell, natural killer cell-associated and donor-specific antibody (DSA)-selective transcripts in Group 3 compared with Groups 1 and 2. There was no significant difference in gene expression profiles between the Groups 1 and 2. Increased intragraft expression of DSA-selective transcripts was found in the biopsies of C4d- Group 3 @entity0 . Thus, an @entity1 score of 2 or more was significantly associated with a histological diagnosis of acute and chronic @entity2 . Hence, increased intragraft DSA-selective gene transcripts may be used as molecular markers for @entity2 , especially in C4d- biopsies.Kidney International advance online publication, 30 September 2015; doi:10.1038/ki.2015.276.

title: Clinical and molecular significance of XXXX in transplant kidney biopsies.

answer: @entity1


abstract: BACKGROUND: Chitotriosidase has been found to be useful as a @entity2 biomarker. In @entity0 with better outcome lower values were observed. Some subjects have 24-base pair duplication in the chitotriosidase gene ( @entity3 ) that results in the production of inactive enzyme. This might influence the outcome of @entity2 and account for described observations. OBJECTIVES: The aim of this study was to correlate common @entity3 duplication polymorphism and clinical outcome status in @entity2 (COS). METHODS: This retrospective study comprised 180 @entity0 with @entity2 . COS at 3, 5 and 10 years was determined and correlated with @entity3 24-base pair duplication polymorphism. @entity3 genotyping was done by the PCR method. RESULTS: There was no significant correlation between @entity3 24-base pair duplication polymorphism and COS at 3, 5 or 10 years but a subgroup analysis showed higher frequency of @entity0 with @entity1 (50% vs. 17.1%) and better COS in @entity3 24-base pair duplication homozygotes vs. all other subjects in major COS groups (no, minimal and persistent disease) at 3 years (p=0.025) and borderline significant at 5 years (p = 0.090). CONCLUSIONS: In this study no correlation between @entity3 24-base pair duplication polymorphism and COS was shown, but possible protective role of homozygous condition for @entity3 24-base pair duplication polymorphism is suggested.

title: Common chitotriosidase duplication gene polymorphism and clinical outcome status in XXXX .

answer: @entity2


abstract: BACKGROUND: @entity4 and @entity3 demonstrate significant morbidity and mortality. Predicting disease progression is challenging in both diseases.   OBJECTIVES: We sought a serum biomarker that could identify @entity0 with @entity4 or @entity3 and prospectively predict short-term decline in lung function in these @entity0 .   METHODS: 10 healthy controls, 5 SSc w/o @entity4 , 6 @entity4 and 13 @entity3 @entity0 underwent venesection. An array of cytokines including @entity2 , @entity5 and @entity1 were measured.   PFTs were obtained at baseline and six months. Cytokine measurements were correlated with PFTs.   RESULTS: @entity2 in @entity3 @entity0 (633ng/ml, IQR 492-1675) was significantly elevated compared to controls (198ng/ml, IQR 52-360, p<0.01) and SSc w/o @entity4 @entity0 (192ng/ml, IQR 0-524, p<0.05); @entity2 in @entity4 @entity0 (836ng/ml, IQR 431-1303) was significantly higher than in controls (p<0.05). @entity5 was significantly higher in @entity3 @entity0 (542ng/ml, IQR 305-577) compared to controls (137ng/ml, IQR 97-284, p<0.01) or to SSc w/o @entity4 @entity0 (169ng/ml, IQR 137-219, p<0.05). In comparison with controls (0.0ng/ml, IQR 0.0-0.6), @entity1 was significantly higher in both @entity3 @entity0 (2.85ng/ml, IQR 1.5-3.6, p<0.05) and @entity4 @entity0 (5.41ng/ml, IQR 2.6-7.2, p<0.001). Using a cut-off level of 459ng/ml for @entity2 and of 1.28ng/ml for @entity1 , 18 out of 19 @entity0 with @entity4 had a serum value of either @entity2 or @entity1 above these thresholds. For all @entity4 patients, baseline serum @entity5 correlated with   FVC %pred over six months (r=-0.63, p=0.005, 95% CI -0.85 to -0.24).   CONCLUSIONS: Combining @entity2 with @entity1 may be a useful screening tool for @entity0 at risk of @entity4 . @entity5 may predict short-term decline in lung function.

title: Biomarkers to identify XXXX and predict lung function decline in scleroderma lung disease or @entity3 .

answer: @entity4


abstract: BACKGROUND: @entity4 and @entity3 demonstrate significant morbidity and mortality. Predicting disease progression is challenging in both diseases.   OBJECTIVES: We sought a serum biomarker that could identify @entity0 with @entity4 or @entity3 and prospectively predict short-term decline in lung function in these @entity0 .   METHODS: 10 healthy controls, 5 SSc w/o @entity4 , 6 @entity4 and 13 @entity3 @entity0 underwent venesection. An array of cytokines including @entity2 , @entity5 and @entity1 were measured.   PFTs were obtained at baseline and six months. Cytokine measurements were correlated with PFTs.   RESULTS: @entity2 in @entity3 @entity0 (633ng/ml, IQR 492-1675) was significantly elevated compared to controls (198ng/ml, IQR 52-360, p<0.01) and SSc w/o @entity4 @entity0 (192ng/ml, IQR 0-524, p<0.05); @entity2 in @entity4 @entity0 (836ng/ml, IQR 431-1303) was significantly higher than in controls (p<0.05). @entity5 was significantly higher in @entity3 @entity0 (542ng/ml, IQR 305-577) compared to controls (137ng/ml, IQR 97-284, p<0.01) or to SSc w/o @entity4 @entity0 (169ng/ml, IQR 137-219, p<0.05). In comparison with controls (0.0ng/ml, IQR 0.0-0.6), @entity1 was significantly higher in both @entity3 @entity0 (2.85ng/ml, IQR 1.5-3.6, p<0.05) and @entity4 @entity0 (5.41ng/ml, IQR 2.6-7.2, p<0.001). Using a cut-off level of 459ng/ml for @entity2 and of 1.28ng/ml for @entity1 , 18 out of 19 @entity0 with @entity4 had a serum value of either @entity2 or @entity1 above these thresholds. For all @entity4 patients, baseline serum @entity5 correlated with   FVC %pred over six months (r=-0.63, p=0.005, 95% CI -0.85 to -0.24).   CONCLUSIONS: Combining @entity2 with @entity1 may be a useful screening tool for @entity0 at risk of @entity4 . @entity5 may predict short-term decline in lung function.

title: Biomarkers to identify @entity4 and predict lung function decline in scleroderma lung disease or XXXX .

answer: @entity3


abstract: AIM: One of the most promising strategies for the treatment of @entity3 is targeted drug delivery via the @entity4 ( @entity4 ). The success of this approach heavily depends on the @entity4 expression level on parenchymal liver cells. In this study, we assessed the mRNA and protein expression levels of the major receptor subunit, @entity4 , in hepatocytes both in vitro and in vivo. METHODS: In vitro, various @entity1 -derived cell lines were evaluated. In vivo, we screened the @entity4 mRNA on 59 @entity2 and matched non-neoplastic tissue using RNA microarray. In addition, 350 @entity0 liver specimens of @entity0 with @entity2 or non-neoplastic @entity3 were screened for @entity4 protein level using tissue microarray analysis. RESULTS: Our data reveal that the @entity4 mRNA expression directly correlates with the protein level. We demonstrate that the @entity4 expression is upregulated in cirrhotic specimens and is significantly decreased with increasing @entity2 grade. CONCLUSIONS: Since the @entity4 expression levels are variable between @entity0 , our findings suggest that @entity4 -based targeting strategies should be combined with @entity4 -companion diagnostics to maximize clinical benefit. This article is protected by copyright. All rights reserved.

title: Variable asialoglycoprotein-receptor 1 expression in XXXX : Implications for therapeutic intervention.

answer: @entity3


abstract: BACKGROUND: @entity5 (AI) can occur after unilateral adrenalectomy for adrenal-dependent @entity1 . Postoperative glucocorticoid replacement (GR), although given routinely, may not be necessary. We sought to identify factors that, in combination with postoperative day 1 cosyntropin stimulation testing ( @entity3 -CST), would predict the need for GR. METHODS: We reviewed 31 consecutive @entity0 who underwent unilateral adrenalectomy for @entity1 (study @entity0 ) or @entity4 (control @entity0 ). A standard @entity3 -CST protocol was used. @entity2 was started for clinical evidence of AI, basal plasma @entity2  <=5 ( g/dL), or a stimulated plasma @entity2 <18. RESULTS: A normal @entity3 -CST was found in all nine control @entity0 and 11 of 22 @entity0 (50%) with @entity1 ; the other 11 study @entity0 (50%) received GR based on the @entity3 -CST. These @entity0 were younger (51 vs 62  years; P  =  .017), had a higher body mass index (BMI; 31 vs 29  kg/m(2)), and smaller @entity6 (16.9 vs 33.0  g; P  =  .009) than non-GR study @entity0 . CONCLUSION: After unilateral adrenalectomy for @entity1 , only 50% of @entity0 received GR. No preoperative biochemical characteristics were associated with postoperative AI, although @entity0 who received GR were younger, and tended to have a higher BMI and smaller adrenal nodules. Use of this novel protocol for postoperative dynamic adrenal function testing prevented unnecessary GR in 50% of @entity0 and allowed for individualized @entity0 care.

title: Cosyntropin stimulation testing on postoperative day 1 allows for selective glucocorticoid replacement therapy after adrenalectomy for XXXX : Results of a novel, multidisciplinary institutional protocol.

answer: @entity1


abstract: UNASSIGNED: Abstract Background: Adolescent @entity1 is a @entity2 that is impacted from each @entity0 's biopsychosocial milieu. Successfully treating @entity4 requires long-term, innovative, systematic involvement to facilitate @entity0 and family engagement and change. Methods: Extensive chart review was done for three @entity1 adolescents who underwent comprehensive weight management in an adolescent clinic seen within the past 5 years. The charts were reviewed starting from the time of initial contact through the last visit in the clinic. The @entity0 are no longer receiving care within the clinic. Results: The @entity0 presented with BMI>99th percentile, family history of @entity1 , severe @entity3 , and multiple @entity1 -related comorbidities. Their treatment involved comprehensive multidisciplinary intervention in an adolescent weight management clinic within a tertiary care center. In addition to rigorous support through frequent office visits, these @entity0 all eventually required temporary, alternative living arrangements to successfully implement recommendations. One @entity0 resided with another family member; two went to inpatient weight management program care for 2-3 months. All subjects successfully lost weight when away from their primary residence, and they demonstrated improvement or resolution of comorbidities. Conclusions: This case series of three adolescents who underwent comprehensive @entity1 evaluation and treatment demonstrates multidisciplinary care across interconnected treatment programs and active engagement of family. Those who maintained successful weight loss reduced sedentary time, demonstrated family support (e.g., key members attending follow-up visits), and altered their living environment and were committed to their own health goals.

title: XXXX and treatment of three adolescents: a case series.

answer: @entity1


abstract: BACKGROUND: Various techniques for lengthening short columellae have been used for bilateral @entity1 repair. However, previous methods have not yielded satisfactory results. We performed a full-thickness skin graft to lengthen short columellae during secondary @entity1 repair in adult @entity0 . METHODS: Ten bilateral cleft @entity2 and nose @entity0 underwent secondary cheiloplasty with open rhinoplasty between July 2008 and August 2014. The @entity0 underwent a full-thickness skin graft on the medial crura to elongate the columella. The average age of the @entity0 at the time of surgery was 22.2 years. Nasal profiles were evaluated before and after the operation using the photogrammetric method. RESULTS: The nasal profiles were improved in all @entity0 , and all skin grafts were well taken, with the exception of one @entity0 . Columellar height, nostril height, and columella- @entity2 angle increased, and nasal width decreased significantly. The ratios of columellar height to nasal height, columellar height to nasal width, and nasal height to nasal width increased to a statistically significant extent. CONCLUSIONS: Columella lengthening with a full-thickness skin graft is a simple and effective method for the repair of severely short columellae in bilateral @entity1 @entity0 . We had satisfactory outcomes, with good color matching and aesthetically pleasing contours.

title: Columella Lengthening with a Full-Thickness Skin Graft for Secondary Bilateral Cleft XXXX and Nose Repair.

answer: @entity2


abstract: BACKGROUND: Serum thyroid stimulating hormone (TSH) levels are frequently elevated in @entity1 @entity0 and are most likely to be associated with @entity5 resistance. However, clinical relevance of this association remains unclear. OBJECTIVES: To assess the prevalence of hyperthyrotropinemia; to analyze the relationship between TSH and homeostasis model assessment - @entity5 resistance (HOMA-IR); and to verify whether TSH levels and HOMA-IR vary with @entity3 in @entity1 @entity0 . SUBJECTS AND METHODS: Retrospective longitudinal study with data from baseline and 1 year after lifestyle intervention in a pediatric @entity1 group (344 @entity0 were recruited and 100 among them completed follow-up). For postintervention analysis, three groups were considered according to body mass index-standard deviation score (BMI- @entity2 ) variations:  <=-0.5 (significant @entity3 ); 0.5-0 ( @entity3 ); and >0 ( @entity4 ). Statistical analysis was performed using SPSS 19.0  . RESULTS: The prevalence of increased TSH levels was 9.3%. At baseline TSH (p=0.007), fT4 (p=0.006), and HOMA-IR (p<0.001) were positively correlated to BMI- @entity2 (n=344). Weight reduction was verified in 67 out of 100 cases but significant loss was present in only 21 cases. Decreases in both TSH and BMI- @entity2 were independently associated with decreases in HOMA-IR (p=0.005 and p=0.016, respectively). There was no correlation between TSH and BMI- @entity2 variation. Significant decreases in the HOMA-IR (p=0.006) were only achieved in the significant @entity3 group. CONCLUSIONS: The prevalence of hyperthyrotropinemia was lower than previously reported. However, cutoff values were adjusted to pubertal stage, suggesting an over report in other studies. @entity5 resistance and TSH were positively correlated, independent of body status. Although @entity3 was not associated with TSH variation, a decrease in TSH levels was independently associated with decreases in HOMA-IR.

title: XXXX , thyroid function, and @entity5 resistance - is there a link? A longitudinal study.

answer: @entity1


abstract: BACKGROUND: Serum thyroid stimulating hormone (TSH) levels are frequently elevated in @entity1 @entity0 and are most likely to be associated with @entity5 resistance. However, clinical relevance of this association remains unclear. OBJECTIVES: To assess the prevalence of hyperthyrotropinemia; to analyze the relationship between TSH and homeostasis model assessment - @entity5 resistance (HOMA-IR); and to verify whether TSH levels and HOMA-IR vary with @entity3 in @entity1 @entity0 . SUBJECTS AND METHODS: Retrospective longitudinal study with data from baseline and 1 year after lifestyle intervention in a pediatric @entity1 group (344 @entity0 were recruited and 100 among them completed follow-up). For postintervention analysis, three groups were considered according to body mass index-standard deviation score (BMI- @entity2 ) variations:  <=-0.5 (significant @entity3 ); 0.5-0 ( @entity3 ); and >0 ( @entity4 ). Statistical analysis was performed using SPSS 19.0  . RESULTS: The prevalence of increased TSH levels was 9.3%. At baseline TSH (p=0.007), fT4 (p=0.006), and HOMA-IR (p<0.001) were positively correlated to BMI- @entity2 (n=344). Weight reduction was verified in 67 out of 100 cases but significant loss was present in only 21 cases. Decreases in both TSH and BMI- @entity2 were independently associated with decreases in HOMA-IR (p=0.005 and p=0.016, respectively). There was no correlation between TSH and BMI- @entity2 variation. Significant decreases in the HOMA-IR (p=0.006) were only achieved in the significant @entity3 group. CONCLUSIONS: The prevalence of hyperthyrotropinemia was lower than previously reported. However, cutoff values were adjusted to pubertal stage, suggesting an over report in other studies. @entity5 resistance and TSH were positively correlated, independent of body status. Although @entity3 was not associated with TSH variation, a decrease in TSH levels was independently associated with decreases in HOMA-IR.

title: @entity1 , thyroid function, and XXXX resistance - is there a link? A longitudinal study.

answer: @entity5


abstract: Recent taxonomic reexamination of @entity0 strains as defined in the 8th edition of Bergey's Manual of Determinative Bacteriology allowed to distinguish 5 species among these strains: @entity0 , L. innocua, @entity4 , @entity2 , and @entity3 . As till now only the behaviour of the species @entity0 , L. innocua, and @entity4 towards bacteriophages was characterized, the present study aimed at the search for phages occurring on these two new species and to determine their lytic activities towards representative strains of the whole genus. Seven different bacteriophages were isolated from the culture filtrates of 45 strains of @entity3 , whereas only one phage was obtained from the filtrates of 17 strains of @entity2 . No phage was isolated from the filtrates of @entity1 and @entity1 strains with our methods. The phage preparations proved stable over a period of 6 to 12 months with titers ranging from 7 X 10(8) to 5 X 10(10). By use of a set of lytic phages which contained in addition to the eight new phages from @entity2 and @entity3 23 known phages from @entity0 , L. innocua, and @entity4 , 511 selected strains, originating from various sources, especially environment (125 strains), and belonging to all species of Listeria, were studied. 345 (68%) of the 511 strains could be assigned to a lysovar by means of the extended set. The eight new phages showed genus- and serogroup specificity but did not present species-specific reactions. The strains of @entity1 and @entity1 were untypable using these 31 phages. No relationship between lysovar and serovar on the one side and host and geographic source on the other side was apparent.

title: [Isolation of Listeria seeligeri and XXXX bacteriophages. Lysotyping of @entity0 , L. ivanovii, L. innocua, @entity3 and @entity2 ].

answer: @entity2


abstract: Recent taxonomic reexamination of @entity0 strains as defined in the 8th edition of Bergey's Manual of Determinative Bacteriology allowed to distinguish 5 species among these strains: @entity0 , L. innocua, @entity4 , @entity2 , and @entity3 . As till now only the behaviour of the species @entity0 , L. innocua, and @entity4 towards bacteriophages was characterized, the present study aimed at the search for phages occurring on these two new species and to determine their lytic activities towards representative strains of the whole genus. Seven different bacteriophages were isolated from the culture filtrates of 45 strains of @entity3 , whereas only one phage was obtained from the filtrates of 17 strains of @entity2 . No phage was isolated from the filtrates of @entity1 and @entity1 strains with our methods. The phage preparations proved stable over a period of 6 to 12 months with titers ranging from 7 X 10(8) to 5 X 10(10). By use of a set of lytic phages which contained in addition to the eight new phages from @entity2 and @entity3 23 known phages from @entity0 , L. innocua, and @entity4 , 511 selected strains, originating from various sources, especially environment (125 strains), and belonging to all species of Listeria, were studied. 345 (68%) of the 511 strains could be assigned to a lysovar by means of the extended set. The eight new phages showed genus- and serogroup specificity but did not present species-specific reactions. The strains of @entity1 and @entity1 were untypable using these 31 phages. No relationship between lysovar and serovar on the one side and host and geographic source on the other side was apparent.

title: [Isolation of Listeria seeligeri and @entity2 bacteriophages. Lysotyping of @entity0 , L. ivanovii, L. innocua, @entity3 and XXXX ].

answer: @entity2


abstract: Recent taxonomic reexamination of @entity0 strains as defined in the 8th edition of Bergey's Manual of Determinative Bacteriology allowed to distinguish 5 species among these strains: @entity0 , L. innocua, @entity4 , @entity2 , and @entity3 . As till now only the behaviour of the species @entity0 , L. innocua, and @entity4 towards bacteriophages was characterized, the present study aimed at the search for phages occurring on these two new species and to determine their lytic activities towards representative strains of the whole genus. Seven different bacteriophages were isolated from the culture filtrates of 45 strains of @entity3 , whereas only one phage was obtained from the filtrates of 17 strains of @entity2 . No phage was isolated from the filtrates of @entity1 and @entity1 strains with our methods. The phage preparations proved stable over a period of 6 to 12 months with titers ranging from 7 X 10(8) to 5 X 10(10). By use of a set of lytic phages which contained in addition to the eight new phages from @entity2 and @entity3 23 known phages from @entity0 , L. innocua, and @entity4 , 511 selected strains, originating from various sources, especially environment (125 strains), and belonging to all species of Listeria, were studied. 345 (68%) of the 511 strains could be assigned to a lysovar by means of the extended set. The eight new phages showed genus- and serogroup specificity but did not present species-specific reactions. The strains of @entity1 and @entity1 were untypable using these 31 phages. No relationship between lysovar and serovar on the one side and host and geographic source on the other side was apparent.

title: [Isolation of Listeria seeligeri and @entity2 bacteriophages. Lysotyping of @entity0 , L. ivanovii, L. innocua, XXXX and @entity2 ].

answer: @entity3


abstract: Recent taxonomic reexamination of @entity0 strains as defined in the 8th edition of Bergey's Manual of Determinative Bacteriology allowed to distinguish 5 species among these strains: @entity0 , L. innocua, @entity4 , @entity2 , and @entity3 . As till now only the behaviour of the species @entity0 , L. innocua, and @entity4 towards bacteriophages was characterized, the present study aimed at the search for phages occurring on these two new species and to determine their lytic activities towards representative strains of the whole genus. Seven different bacteriophages were isolated from the culture filtrates of 45 strains of @entity3 , whereas only one phage was obtained from the filtrates of 17 strains of @entity2 . No phage was isolated from the filtrates of @entity1 and @entity1 strains with our methods. The phage preparations proved stable over a period of 6 to 12 months with titers ranging from 7 X 10(8) to 5 X 10(10). By use of a set of lytic phages which contained in addition to the eight new phages from @entity2 and @entity3 23 known phages from @entity0 , L. innocua, and @entity4 , 511 selected strains, originating from various sources, especially environment (125 strains), and belonging to all species of Listeria, were studied. 345 (68%) of the 511 strains could be assigned to a lysovar by means of the extended set. The eight new phages showed genus- and serogroup specificity but did not present species-specific reactions. The strains of @entity1 and @entity1 were untypable using these 31 phages. No relationship between lysovar and serovar on the one side and host and geographic source on the other side was apparent.

title: [Isolation of Listeria seeligeri and @entity2 bacteriophages. Lysotyping of XXXX , L. ivanovii, L. innocua, @entity3 and @entity2 ].

answer: @entity0


abstract: The Kaunitz' procedure in the surgical treatment of @entity2 associated with a @entity3 . In @entity0 with pathological @entity2 associated with a @entity3 , simple repositioning of the lower esophageal sphincter (L.E.S.) without fundoplication can restore the competence of the L.E.S., provided there is adequate mobilisation of the esophagus and fixation to strong tissues. The procedure proposed by Kaunitz consists of a left thoracotomy, with fixation of the gastroesophageal junction to the diaphragm. In the period May 74-May 83 we performed the procedure on 85 @entity0 . There was no operative mortality and a low early complication rate. All but one @entity0 showed a good repositioning on the postoperative barium swallow and improved dramatically, with complete cessation of reflux symptoms. Seventy-eight @entity0 (92,8%) are followed up regularly by means of a standard questionnaire, barium swallow and esophagoscopy. At this stage of the study, with follow-up periods ranging from 6 months to 9 years, 65 @entity0 (83,3%) show an excellent result, six (7,7%) are greatly improved, with disappearance of the preoperatively existing @entity4 , but keep some mild @entity1 . In one @entity0 repositioning was impossible. Six recurrences were noted, four of them in @entity0 operated during the early period of our experience with the Kaunitz technique. This simple and effective procedure is a valuable alternative in the surgical treatment of pathological @entity2 .

title: [The treatment of XXXX using the Kaunitz technic].

answer: @entity2


abstract: OBJECTIVE: To describe the incidence and risk factors for evolution of postpartum @entity2 towards severe. MATERIAL AND METHODS: Epidemiologic, observational, analytical, case-control study was done from total data of deliveries in Complexo Hospitalario de Our  nse between January 1st 2004 and June 30th 2014. Mann-Whitney U test was used to determine the differences between cases and controls. The statistical analyses were made with the informatic programs Spss 15.0 y Epidat 3.0. We considered statistical significance for p < 0.05. RESULTS: The initial size of the sample was 17,116 deliveries from which we selected 150 @entity0 with the diagnosis of postpartum @entity2 . The incidence for @entity3 form all deliveries was 3.3% reaching 36% of the total of postpartum @entity2 . 79.63% of @entity3 showed symptoms withing the first 24h postpartum, but we found that 20.37% debuted as secondary postpartum @entity2 . BMI >=  35, @entity1 gestational manifestations, labor's second phase >=  120 minutes and weight at birth > 4000 g presented statistical significance as risk factor for evolution to severe postpartum haemhorrage. The relative risk for evolution towards @entity3 was 2.81 for instrumental delivery and 3.55 for cesarean section. The most prevalent etiology was uterine atony. CONCLUSION: The incidence of @entity3 in our hospital is low, as well as secondary maternal mortality. The major risk factor for the appearance of the clinical symptoms is cesarean section, followed, in less proportion by instrumental delivery. It is possible for the @entity3 to make its appearance delayed after delivery, usually secondary to infrequent and non well-known clinical presentations.

title: [Risk factors of evolution of postpartum XXXX towards severe postpartum @entity2 : A case-control study].

answer: @entity2


abstract: OBJECTIVE: To describe the incidence and risk factors for evolution of postpartum @entity2 towards severe. MATERIAL AND METHODS: Epidemiologic, observational, analytical, case-control study was done from total data of deliveries in Complexo Hospitalario de Our  nse between January 1st 2004 and June 30th 2014. Mann-Whitney U test was used to determine the differences between cases and controls. The statistical analyses were made with the informatic programs Spss 15.0 y Epidat 3.0. We considered statistical significance for p < 0.05. RESULTS: The initial size of the sample was 17,116 deliveries from which we selected 150 @entity0 with the diagnosis of postpartum @entity2 . The incidence for @entity3 form all deliveries was 3.3% reaching 36% of the total of postpartum @entity2 . 79.63% of @entity3 showed symptoms withing the first 24h postpartum, but we found that 20.37% debuted as secondary postpartum @entity2 . BMI >=  35, @entity1 gestational manifestations, labor's second phase >=  120 minutes and weight at birth > 4000 g presented statistical significance as risk factor for evolution to severe postpartum haemhorrage. The relative risk for evolution towards @entity3 was 2.81 for instrumental delivery and 3.55 for cesarean section. The most prevalent etiology was uterine atony. CONCLUSION: The incidence of @entity3 in our hospital is low, as well as secondary maternal mortality. The major risk factor for the appearance of the clinical symptoms is cesarean section, followed, in less proportion by instrumental delivery. It is possible for the @entity3 to make its appearance delayed after delivery, usually secondary to infrequent and non well-known clinical presentations.

title: [Risk factors of evolution of postpartum @entity2 towards severe postpartum XXXX : A case-control study].

answer: @entity2


abstract: In order to investigate the effect of preoperative pulmonary function exerted on the @entity1 , postoperative chest X-ray films were consecutively studied in terms of abnormal shadows in the lung up to the 30th postoperative day (p.o.d.) in a series of 60 @entity0 with @entity3 . @entity0 were divided into 3 groups according to their preoperative % VC and FEV1.0%; @entity0 with % VC greater than or equal to 100% and FEV1.0% greater than or equal to 80% were stratified as group A, those with % VC greater than or equal to 80% and FEV1.0% greater than or equal to 70% excluding group A as group B, and those with % VC less than 80% or FEV1.0% less than 70% as group C. @entity0 with pyothorax secondary to anastomotic leakage, and/or @entity4 due to proven @entity2 were excluded. Abnormal shadows on the chest X-ray were observed in 68.3% of all the @entity0 after surgery. The positive ratios for those shadows were not statistically different among the three groups. Before 3rd p.o.d., preoperative pulmonary function did not correlate with the positive ratio for abnormal shadows of each group. After 5th p.o.d., however, the positive ratios in group C were higher than those in group A and B up to 14th p.o.d. (p less than 0.05). Approximately seventy per cent of all abnormal shadows started within 3 days after the operation. Abnormal shadows first appeared on the upper lung fields more frequently in group C than in group A + B (p less than 0.01). The abnormal shadows on the right lower lung field appeared significantly later than those on the right upper lung field (p less than 0.05). In group C, major abnormal shadows were found in 71.4%, which were higher than those in group A and B (p less than 0.05). The abnormal shadows in group C persisted for a period of 14 days, which was longer than those in group A and B (p less than 0.05). In conclusion, preoperative pulmonary function exerts much influence on the progress and continuity of abnormal shadows in the lung after 5th p.o.d. in @entity0 with @entity3 .

title: [Pulmonary complications after XXXX surgery through right thoracic approach].

answer: @entity3


abstract: OBJECTIVE: @entity4 is the most common complication after colectomy with ileal pouch-anal @entity1 (IPAA) for UC and the risk is the highest within the 1st year after surgery. The pathogenesis is not completely understood but clinical response to antibiotics suggests a role for gut microbiota. We hypothesised that the risk for @entity4 can be predicted based on the faecal microbial composition before colectomy. DESIGN: Faecal samples from 21 @entity0 with UC undergoing IPAA were prospectively collected before colectomy and at predefined clinical visits at 1 month, 3 months, 6 months and 12   months after IPAA. The predominant microbiota was analysed using community profiling with denaturing gradient gel electrophoresis followed by quantitative real-time PCR validation. RESULTS: Cluster analysis before colectomy distinguished @entity0 with @entity4 from those with normal pouch during the 1st year of follow-up. In @entity0 developing @entity4 , an increase of Ruminococcus gnavus (p<0.001), @entity3 (p=0.043), @entity2 (p=0.011) and a reduction of two Lachnospiraceae genera (Blautia (p=0.04), Roseburia (p=0.008)) was observed. A score combining these five bacterial risk factors was calculated and presence of at least two risk factors showed a sensitivity and specificity of 100% and 63.6%, respectively. CONCLUSIONS: Presence of R. gnavus, @entity3 and @entity2 and absence of Blautia and Roseburia in faecal samples of @entity0 with UC before surgery is associated with a higher risk of @entity4 after IPAA. Our findings suggest new predictive and therapeutic strategies in @entity0 undergoing colectomy with IPAA.

title: Specific members of the predominant gut microbiota predict XXXX following colectomy and IPAA in UC.

answer: @entity4


abstract: Genetic diversity within a species is a common feature, which plays a vital role in its survival and adaptability, and is important for the identification and authentication of a species. Lonicera japonica is a traditionally used medicinal plant, which have been recently genetically characterized by an improved ran- dom amplified polymorphic DNA (RAPD) analysis. In this study, the molecular markers on the basis of these RAPD fragments have been developed to identify specific @entity1 variety. The DNAs were extracted from fresh young leaves of different samples of @entity1 collected from Shenzhen, Yichang, Leshan, Emei and Loudi, China. The DNA materials were amplified using improved RAPD PCR. Different RAPD bands were excised, cloned and developed for stable @entity0 ( @entity0 ) markers with differ- ent species. Two @entity0 markers, JYH3-3 and JYH4-3, have been successfully cloned from improved.RAPD fragments. The @entity0 marker JYH3-3 was found specific for all of the @entity1 samples collected from the different regions, and another marker JYH 4-3 was strictly specific to the Shenzhen sample from Guangdong province, which is geographically distant from Hubei, Sichuan and Hunan Provinces (source of other @entity1 samples). The marker JYH3-3 was found as specific molecular marker for the identification of @entity1 , while JYH4-3 was found as molecular marker strictly specific for the Shenzhen sample. The developed @entity0 markers might serve as more specific molecular markers for @entity1 variety authentication. The combination of improved RAPD analysis and @entity0 marker development have resulted useful tools to study the genetic variety of any organism, which we have successfully applied here in @entity1 .

title: Development of RAPD- XXXX markers for Lonicera japonica (Caprifolicaceae) variety authentication by improved RAPD and DNA cloning.

answer: @entity0


abstract: PURPOSE: @entity4 , @entity3 , and @entity5 (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) @entity2 and is associated with significant @entity1 . We examined the safety and efficacy of a modified DCF (mDCF) regimen in a randomized multicenter phase II study. @entity0 AND METHODS: Previously untreated @entity0 with metastatic gastric or GEJ @entity2 were randomly assigned to receive either mDCF ( @entity5 2,000 mg/m(2) intravenously [IV] every 48 hours, @entity4 40 mg/m(2) IV on day 1, @entity3 40 mg/m(2) IV on day 3, every 2 weeks) or parent DCF ( @entity4 75 mg/m(2), @entity3 75 mg/m(2), and @entity5 750 mg/m(2) IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks). The study had 90% power to differentiate between 6-month progression-free survival of 26% and 43%, with type I and II error rates of 10% each. An early stopping rule for @entity1 was included, defined as grade 3 to 4 adverse event rate > 70% in the first 3 months. RESULTS: From November 2006 to June 2010, 85 evaluable @entity0 were enrolled (male, n = 61; female, n = 24; median age, 58 years; Karnofsky performance status, 90%; GEJ, n = 28; gastric, 57). mDCF (n = 54) @entity1 rates included 54% grade 3 to 4 @entity1 (22% hospitalized) within the first 3 months and 76% grade 3 to 4 @entity1 over the course of treatment. The DCF arm (n = 31) closed early because of @entity1 , with rates of 71% grade 3 to 4 @entity1 (52% hospitalized) within 3 months and 90% grade 3 to 4 @entity1 over the course of treatment. Six-month PFS was 63% (95% CI, 48% to 75%) for mDCF and 53% (95% CI, 34% to 69%) for DCF. Median overall survival was improved for mDCF (18.8 v 12.6 months; P = .007). CONCLUSION: mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for @entity0 with metastatic gastric or GEJ @entity2 .

title: Randomized Multicenter Phase II Study of Modified @entity4 , XXXX , and @entity5 (DCF) Versus DCF Plus Growth Factor Support in @entity0 With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

answer: @entity3


abstract: PURPOSE: @entity4 , @entity3 , and @entity5 (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) @entity2 and is associated with significant @entity1 . We examined the safety and efficacy of a modified DCF (mDCF) regimen in a randomized multicenter phase II study. @entity0 AND METHODS: Previously untreated @entity0 with metastatic gastric or GEJ @entity2 were randomly assigned to receive either mDCF ( @entity5 2,000 mg/m(2) intravenously [IV] every 48 hours, @entity4 40 mg/m(2) IV on day 1, @entity3 40 mg/m(2) IV on day 3, every 2 weeks) or parent DCF ( @entity4 75 mg/m(2), @entity3 75 mg/m(2), and @entity5 750 mg/m(2) IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks). The study had 90% power to differentiate between 6-month progression-free survival of 26% and 43%, with type I and II error rates of 10% each. An early stopping rule for @entity1 was included, defined as grade 3 to 4 adverse event rate > 70% in the first 3 months. RESULTS: From November 2006 to June 2010, 85 evaluable @entity0 were enrolled (male, n = 61; female, n = 24; median age, 58 years; Karnofsky performance status, 90%; GEJ, n = 28; gastric, 57). mDCF (n = 54) @entity1 rates included 54% grade 3 to 4 @entity1 (22% hospitalized) within the first 3 months and 76% grade 3 to 4 @entity1 over the course of treatment. The DCF arm (n = 31) closed early because of @entity1 , with rates of 71% grade 3 to 4 @entity1 (52% hospitalized) within 3 months and 90% grade 3 to 4 @entity1 over the course of treatment. Six-month PFS was 63% (95% CI, 48% to 75%) for mDCF and 53% (95% CI, 34% to 69%) for DCF. Median overall survival was improved for mDCF (18.8 v 12.6 months; P = .007). CONCLUSION: mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for @entity0 with metastatic gastric or GEJ @entity2 .

title: Randomized Multicenter Phase II Study of Modified @entity4 , @entity3 , and @entity5 (DCF) Versus DCF Plus Growth Factor Support in XXXX With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

answer: @entity0


abstract: PURPOSE: @entity4 , @entity3 , and @entity5 (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) @entity2 and is associated with significant @entity1 . We examined the safety and efficacy of a modified DCF (mDCF) regimen in a randomized multicenter phase II study. @entity0 AND METHODS: Previously untreated @entity0 with metastatic gastric or GEJ @entity2 were randomly assigned to receive either mDCF ( @entity5 2,000 mg/m(2) intravenously [IV] every 48 hours, @entity4 40 mg/m(2) IV on day 1, @entity3 40 mg/m(2) IV on day 3, every 2 weeks) or parent DCF ( @entity4 75 mg/m(2), @entity3 75 mg/m(2), and @entity5 750 mg/m(2) IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks). The study had 90% power to differentiate between 6-month progression-free survival of 26% and 43%, with type I and II error rates of 10% each. An early stopping rule for @entity1 was included, defined as grade 3 to 4 adverse event rate > 70% in the first 3 months. RESULTS: From November 2006 to June 2010, 85 evaluable @entity0 were enrolled (male, n = 61; female, n = 24; median age, 58 years; Karnofsky performance status, 90%; GEJ, n = 28; gastric, 57). mDCF (n = 54) @entity1 rates included 54% grade 3 to 4 @entity1 (22% hospitalized) within the first 3 months and 76% grade 3 to 4 @entity1 over the course of treatment. The DCF arm (n = 31) closed early because of @entity1 , with rates of 71% grade 3 to 4 @entity1 (52% hospitalized) within 3 months and 90% grade 3 to 4 @entity1 over the course of treatment. Six-month PFS was 63% (95% CI, 48% to 75%) for mDCF and 53% (95% CI, 34% to 69%) for DCF. Median overall survival was improved for mDCF (18.8 v 12.6 months; P = .007). CONCLUSION: mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for @entity0 with metastatic gastric or GEJ @entity2 .

title: Randomized Multicenter Phase II Study of Modified @entity4 , @entity3 , and XXXX (DCF) Versus DCF Plus Growth Factor Support in @entity0 With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

answer: @entity5


abstract: PURPOSE: @entity4 , @entity3 , and @entity5 (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) @entity2 and is associated with significant @entity1 . We examined the safety and efficacy of a modified DCF (mDCF) regimen in a randomized multicenter phase II study. @entity0 AND METHODS: Previously untreated @entity0 with metastatic gastric or GEJ @entity2 were randomly assigned to receive either mDCF ( @entity5 2,000 mg/m(2) intravenously [IV] every 48 hours, @entity4 40 mg/m(2) IV on day 1, @entity3 40 mg/m(2) IV on day 3, every 2 weeks) or parent DCF ( @entity4 75 mg/m(2), @entity3 75 mg/m(2), and @entity5 750 mg/m(2) IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks). The study had 90% power to differentiate between 6-month progression-free survival of 26% and 43%, with type I and II error rates of 10% each. An early stopping rule for @entity1 was included, defined as grade 3 to 4 adverse event rate > 70% in the first 3 months. RESULTS: From November 2006 to June 2010, 85 evaluable @entity0 were enrolled (male, n = 61; female, n = 24; median age, 58 years; Karnofsky performance status, 90%; GEJ, n = 28; gastric, 57). mDCF (n = 54) @entity1 rates included 54% grade 3 to 4 @entity1 (22% hospitalized) within the first 3 months and 76% grade 3 to 4 @entity1 over the course of treatment. The DCF arm (n = 31) closed early because of @entity1 , with rates of 71% grade 3 to 4 @entity1 (52% hospitalized) within 3 months and 90% grade 3 to 4 @entity1 over the course of treatment. Six-month PFS was 63% (95% CI, 48% to 75%) for mDCF and 53% (95% CI, 34% to 69%) for DCF. Median overall survival was improved for mDCF (18.8 v 12.6 months; P = .007). CONCLUSION: mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for @entity0 with metastatic gastric or GEJ @entity2 .

title: Randomized Multicenter Phase II Study of Modified XXXX , @entity3 , and @entity5 (DCF) Versus DCF Plus Growth Factor Support in @entity0 With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

answer: @entity4


abstract: UNASSIGNED: In cavernous sinus (CS) surgery, venous complication may occur in some types of venous drainage. The sphenobasal vein (SBV) drains from the superficial middle cerebral vein (SMCV) to the pterygoid venous plexus at the temporal skull base. A frontotemporal epi- and interdural approach (Dolenc approach), which is one of the CS approaches, may damage the SBV's route. We report a case of intracavernous trigeminal schwannoma that contained the SBV and discuss our modified surgical procedure that combined epi- and subdural approaches to preserve the SBV. A 64-year-old @entity0 complained of right progressive @entity4 and was referred to our hospital for surgery. MR images revealed a @entity3 in the right CS. Three-dimensional venography revealed that the SMCV drained into the pterygoid venous plexus via the SBV. After identifying the first branch of the trigeminal nerve epidurally, we incised the dura linearly along the sylvian fissure and entered the subdural space to visualize the SBV. The incision was continued to the meningeal dura of the lateral wall of the CS along the superior margin of the first branch of the trigeminal nerve, and the @entity2 was opened from the subdural side. The @entity1 was grossly totally removed, and the SBV was preserved. In conclusion, a frontotemporal epi- and subdural approach to the intracavernous trigeminal schwannoma can effectively preserve the SBV.

title: Frontotemporal epi- and subdural approach to a cavernous XXXX for sphenobasal vein preservation-technical case report.

answer: @entity1


abstract: Of 167 episodes of spinal epidural neoplastic compression, 86 were treated by operation. The surgical approach was prospectively selected according to the location of the @entity1 in the spinal canal. Decompression was achieved by 61 vertebral body resections (VBRs) and by 25 laminectomies. The indications for operation were: neurological relapse after previous radiotherapy, the need to make a tissue diagnosis, a @entity1 , and @entity2 during radiotherapy. Before VBR, 28% (17 of 61) were still able to walk, 51% (31 of 61) were parAparetic, and 21% (13 of 61) were paraplegic. Bowel and @entity3 was present in 49% (30 of 61). After VBR, the outcome of only 57 procedures was available for evaluation because of the postoperative death of 4 @entity0 . Eighty per cent (46 of 57) were able to walk, 18% (10 of 57) were paraparetic, and 2% (1 of 57) were paraplegic. Ninety-three per cent had normal sphincter control. Before laminectomy, 8% (2 of 25) were ambulatory, 84% (21 of 25) were paraparetic, and 8% (2 of 25) were paraplegic. Bowel and @entity3 was present in 76% (19 of 25). After laminectomy, only 23 procedures were evaluated because of the postoperative death of 2 @entity0 . Thirty-nine per cent (9 of 23) were ambulatory, 35% (8 of 23) were paraparetic, and 26% (6 of 23) were paraplegic. Fifty-seven per cent regained normal sphincter control. The operative mortality was 7% (4 of 61) in VBR and 8% (2 of 25) in laminectomy.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Surgical decompression of anterior and XXXX compressing the spinal cord: a prospective study.

answer: @entity1


abstract: BACKGROUND: @entity2 in the elderly (aged >=   65  years old) is a significant concern with high morbidity, but the pathophysiology remains unclear particularly in late-onset @entity2 . Recent studies suggest staphylococcal enterotoxin IgE (SE-IgE) sensitization to be a risk factor for @entity2 in general populations; however, the associations have not been examined in late-onset elderly @entity2 . OBJECTIVE: We aimed to examine the associations of @entity4 with late-onset @entity2 in the elderly, using a database of elderly @entity2 cohort study. METHODS: A total of 249 elderly @entity0 with @entity2 and 98 controls were analysed. At baseline, @entity0 were assessed for demographics, atopy, induced sputum profiles and comorbidities including @entity1 ( @entity1 ). Serum total IgE and SE-IgE levels were measured. @entity2 severity was assessed on the basis of @entity2 outcomes during a 12-month follow-up period. RESULTS: At baseline, serum SE-IgE concentrations were significantly higher in @entity0 with @entity2 than in controls [median 0.16 (interquartile range 0.04-0.53) vs. 0.10 (0.01-0.19), P  <  0.001]. Elderly @entity2 @entity0 with high SE-IgE levels had specific characteristics of having more severe @entity2 , sputum @entity3 and @entity1 , compared to those with lower SE-IgE levels. In multivariate logistic regression analyses, the associations between serum SE-IgE concentrations and severe @entity2 were significant, independently of covariables [SE-IgE-high (>=   0.35  kU/L) vs. negative (<  0.10  kU/L) group: odds ratio 7.47, 95% confidence interval 1.86-30.03, P  =  0.005]. Multiple correspondence analyses also showed that high serum SE-IgE level had close relationships with severe @entity2 , @entity1 and sputum @entity3 together. CONCLUSIONS AND CLINICAL RELEVANCE: This is the first report on the significant associations of @entity4 with late-onset @entity2 in the elderly, particularly severe @entity3 with @entity1 comorbidity. Our findings indicate a potential implication of SE in the high morbidity burden of elderly @entity2 and suggest clues to the pathogenesis of severe late-onset @entity3 in the elderly.

title: Staphylococcal enterotoxin IgE sensitization in late-onset severe XXXX in the elderly.

answer: @entity3


abstract: UNASSIGNED: The Kidney Allocation System (KAS) aims to improve deceased donor kidney transplant outcomes by matching of donor allografts and kidney recipients using the kidney donor risk index (KDRI) and recipient estimated post-transplant survival (EPTS) indices. In this single-center study, KAS was retroactively applied to 573 adult deceased donor kidney transplants (2004-2012) performed in the extended criteria/standard criteria donor ( @entity2 / @entity1 ) era. Donor KDRI and recipient EPTS were calculated and transplants were analyzed to identify KAS fits. These were defined as allocation of top 20% allografts to top 20% recipients and bottom 80% allografts to bottom 80% recipients. On retroactive calculation, 70.2% of all transplants fit the KAS. Transplants that fit the KAS had inferior 1- and 5-year @entity0 survival (95.5% vs. 98.8%, p=0.048, and 83.4% vs. 91.7%, p=0.018) and similar 1- and 5-year graft survival compared to transplants that did not fit the KAS (91.3% vs. 94.1%, p=0.276, and 72.7% vs. 73.9%, p=0.561). While EPTS correlated with recipient survival (HR=2.96, p<0.001), KDRI correlated with both recipient (HR=3.56, p<0.001) and graft survival (HR=3.23, p<0.001). Overall, retroactive application of the KAS to transplants performed in the @entity2 / @entity1 era did not identify superior @entity0 survival for kidneys allocated in accordance with the KAS. This article is protected by copyright. All rights reserved.

title: Retroactive Application of the new Kidney Allocation System to Renal Transplants performed in the @entity2 / XXXX era.

answer: @entity1


abstract: UNASSIGNED: The Kidney Allocation System (KAS) aims to improve deceased donor kidney transplant outcomes by matching of donor allografts and kidney recipients using the kidney donor risk index (KDRI) and recipient estimated post-transplant survival (EPTS) indices. In this single-center study, KAS was retroactively applied to 573 adult deceased donor kidney transplants (2004-2012) performed in the extended criteria/standard criteria donor ( @entity2 / @entity1 ) era. Donor KDRI and recipient EPTS were calculated and transplants were analyzed to identify KAS fits. These were defined as allocation of top 20% allografts to top 20% recipients and bottom 80% allografts to bottom 80% recipients. On retroactive calculation, 70.2% of all transplants fit the KAS. Transplants that fit the KAS had inferior 1- and 5-year @entity0 survival (95.5% vs. 98.8%, p=0.048, and 83.4% vs. 91.7%, p=0.018) and similar 1- and 5-year graft survival compared to transplants that did not fit the KAS (91.3% vs. 94.1%, p=0.276, and 72.7% vs. 73.9%, p=0.561). While EPTS correlated with recipient survival (HR=2.96, p<0.001), KDRI correlated with both recipient (HR=3.56, p<0.001) and graft survival (HR=3.23, p<0.001). Overall, retroactive application of the KAS to transplants performed in the @entity2 / @entity1 era did not identify superior @entity0 survival for kidneys allocated in accordance with the KAS. This article is protected by copyright. All rights reserved.

title: Retroactive Application of the new Kidney Allocation System to Renal Transplants performed in the XXXX / @entity1 era.

answer: @entity2


abstract: UNASSIGNED: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is widely used in preoperative diagnosis of @entity1 . We investigated the clinical value of DCE-MRI in differential diagnosis of @entity3 . The study involved 48 subjects with surgical pathology-confirmed @entity2 with solid components. Early dynamic phase enhancement performances of the @entity3 in @entity0 were assessed, including the enhancement pattern, time-signal intensity curve (TIC), signal intensity rate at the initial 60  s (SI60), time to peak within 200  s (TTP200), and slope ratio. There were significant differences in enhancement patterns between benign and malignant @entity2 (P   <   0.05). A total of 30 @entity1 (30/31) displayed type I TIC, 8 @entity1 (8/13) showed type III TIC, and significant differences were found in TIC type between @entity3 (P   <   0.01). @entity2 showed lower SI60 (%) and slope ratio, as well as significantly prolonged TTP20, compared to malignant @entity2 (all P   <   0.01). The microvessel count (MVC) of @entity1 was significantly higher than that of @entity1 (P   <   0.05). Receiver operating characteristic (ROC) curve analyses revealed that @entity4 -MRI provided an optimal diagnostic performance with threshold values of SI60 at 83.40  %, TTP200 at 77.65  s, and slope ratio at 4.12. These findings revealed that @entity4 -MRI provides critical information required for differential diagnosis of @entity3 .

title: The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of XXXX .

answer: @entity3